[
  {
    "ts": "2026-01-28T08:09:24+00:00",
    "headline": "Merck Ends Revolution Medicines Talks As Oncology Plans And Valuation Weighed",
    "summary": "Merck paused acquisition discussions with Revolution Medicines after the two sides could not agree on valuation. The halted talks highlight a shift in Merck's approach to expanding its oncology presence as it reassesses potential deals. This development may influence how investors view both Merck's future transactions and broader pharma M&A activity. Merck, traded as NYSE:MRK, enters this chapter with its shares at $107.92 and a 1-year return of 14.9%. Over 5 years, the stock has returned...",
    "url": "https://finance.yahoo.com/news/merck-ends-revolution-medicines-talks-080924264.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "6b3e3b78-e4c3-3502-9832-47acc04287e5",
      "content": {
        "id": "6b3e3b78-e4c3-3502-9832-47acc04287e5",
        "contentType": "STORY",
        "title": "Merck Ends Revolution Medicines Talks As Oncology Plans And Valuation Weighed",
        "description": "",
        "summary": "Merck paused acquisition discussions with Revolution Medicines after the two sides could not agree on valuation. The halted talks highlight a shift in Merck's approach to expanding its oncology presence as it reassesses potential deals. This development may influence how investors view both Merck's future transactions and broader pharma M&A activity. Merck, traded as NYSE:MRK, enters this chapter with its shares at $107.92 and a 1-year return of 14.9%. Over 5 years, the stock has returned...",
        "pubDate": "2026-01-28T08:09:24Z",
        "displayTime": "2026-01-28T08:09:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-ends-revolution-medicines-talks-080924264.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-ends-revolution-medicines-talks-080924264.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "RVMD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]